# Sachi Bioworks Inc.: Phase 1 study in Amyotrophic Lateral Sclerosis (ALS) (40 participants)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Sachi Bioworks Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of Single Ascending Doses of NI112 in Adults With Amyotrophic Lateral Sclerosis (ALS) |
| NCT ID | NCT07906665 |
| Phase | Phase 1 |
| Status | not yet recruiting |
| Conditions | Amyotrophic Lateral Sclerosis (ALS) |
| Intervention types | drug |
| Target enrollment | 40 |
| Site countries | United States |
| Posted | 2026-10-30 |
| Planned start | 2027-01-22 |
| Event | Newly registered study |
| Event date | 2026-10-30 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07906665). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.